ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $7.33 Average PT from Brokerages

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $7.3333.

Several equities analysts have recently commented on the company. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Wall Street Zen downgraded ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Chardan Capital reduced their price objective on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 26th. JonesTrading reduced their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Finally, Weiss Ratings downgraded ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd.

Insider Buying and Selling at ProQR Therapeutics

In other news, Director Bart Filius acquired 150,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were acquired at an average price of $1.54 per share, with a total value of $231,000.00. Following the acquisition, the director directly owned 150,000 shares in the company, valued at approximately $231,000. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Boer Daniel Anton De acquired 150,000 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was purchased at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the completion of the transaction, the chief executive officer owned 300,000 shares in the company, valued at $522,000. The trade was a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 450,000 shares of company stock valued at $730,500. Corporate insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Aberdeen Group plc increased its holdings in shares of ProQR Therapeutics by 28.4% during the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after purchasing an additional 651,853 shares during the period. Ikarian Capital LLC raised its stake in shares of ProQR Therapeutics by 67.2% during the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock valued at $3,014,000 after purchasing an additional 600,000 shares in the last quarter. Privium Fund Management B.V. lifted its holdings in ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after purchasing an additional 359,475 shares during the period. Citadel Advisors LLC lifted its holdings in ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 277,749 shares during the period. Finally, Millennium Management LLC grew its position in ProQR Therapeutics by 80.8% in the 4th quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 194,369 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

NASDAQ PRQR opened at $1.70 on Friday. ProQR Therapeutics has a one year low of $1.33 and a one year high of $3.10. The company has a 50-day simple moving average of $1.62 and a 200-day simple moving average of $1.67. The firm has a market capitalization of $179.11 million, a PE ratio of -3.40 and a beta of 0.04.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. The firm had revenue of $2.35 million for the quarter, compared to analyst estimates of $5.19 million. Equities analysts forecast that ProQR Therapeutics will post -0.52 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.